The White House and the corporate media are buzzing about the latest respiratory season, and boy do they have a chock-full of “cures” advertised for the occasion.
On Tuesday, top White House officials met with pharmaceutical executives today, expressing mutual concern with the availability of RSV vaccines for infants and young children. RSV — which amounts to a mild cold — mortality rates are so low that most studies don’t even bother adding a mortality column. Nonetheless, it’s become the next big scare, with Pharma-Government Health snake oil salesmen fear mongering about sick infants in order to drive demand for new products. Think of the children! “Senior administration officials underscored the importance of manufacturers such as Sanofi and AstraZeneca working to meet demand with a sense of urgency as we head into the winter season,” the readout said, adding that “ RSV immunization, flu vaccine, and updated COVID-19 vaccines ” […]
Read the Whole Article From the Source: www.dossier.today